L1, termed IB101, which was found to form a defined binding pocket that precisely positions the active moiety in a reactive conformation.
SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
(RTTNews) - Biomea Fusion Inc. (BMEA) announced that it has presented new data from its COVALENT-111 study evaluating Icovamenib for type-2 diabetes at the 23rd World Congress on Insulin Resistance, ...
Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency 32 patients from the 100mg and ...
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled ...
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered at 100 mg and 200 mg, with dosing durations up to 12 weeks in ...
For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug before it could work—forcing millions of patients to rely on daily injections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results